Central Nervous System (CNS) Stimulant Drugs Market - North America, Europe, EMEA, APAC : US, Canada, China, Germany, UK - Forecast 2023-2027

Central Nervous System Stimulant Drugs Market Forecast 2023-2027

The central nervous system (CNS) stimulant drugs market size is forecast to increase by USD 6.48 billion, growing at a CAGR of 5.8% between 2022 and 2027. The growth of the market is propelled by various factors. The escalating prevalence of CNS disorders, such as obstructive sleep apnea (OSA) and narcolepsy, drives demand. Additionally, the approval of new stimulants enhances treatment options, meeting evolving patient needs. Moreover, the increasing utilization of stimulants globally signifies expanding therapeutic applications. These factors collectively contribute to the market's growth trajectory, reflecting a rising demand for effective treatments and a promising outlook for CNS stimulant drugs in addressing neurological disorders worldwide.

What will be the size of the Central Nervous System (CNS) Stimulant Drugs Market During the Forecast Period?

To learn more about this report, Download Report Sample

The market refers to the production, sale, and use of pharmaceutical products that stimulate the central nervous system. These drugs, such as Adolescents, Psychiatry, and Sleepless Nights, are commonly used to treat Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy. They work by increasing the levels of certain neurotransmitters in the brain, including dopamine and norephenylenephrine. Chilblains and Sleeps, two major players in the CNS Stimulant Drugs market, offer a range of products for the treatment of ADHD and Narcolepsy. Psychiatry and Seniors also utilize these drugs for various therapeutic purposes. The market for CNS Stimulant Drugs is expected to grow significantly due to the increasing prevalence of ADHD and Narcolepsy, as well as the expanding use of these drugs for off-label purposes.

Market Dynamics and Customer Landscape

The usage of these drugs come with certain risks and challenges. These drugs can lead to dependency and abuse, and their long-term use can have negative effects on the cardiovascular system. As such, it is important for healthcare professionals to carefully consider the risks and benefits of these drugs when prescribing them to patients. In conclusion, the CNS Stimulant Drugs market is a growing industry that offers significant benefits for the treatment of various neurological conditions. However, it is important to carefully consider the risks and challenges associated with these drugs to ensure their safe and effective use. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key  Market Driver

The increasing use of stimulants worldwide is notably driving market growth. The healthcare services sector has experienced significant growth due to the rising prevalence of CNS disorders such as sleep apnea, narcolepsy, and attention-deficit hyperactivity disorder (ADHD). According to Le et al. (2021), the global prevalence of ADHD in children and adolescents ranges from 5.3%-5.9%, with Europe reporting a 4.6% incidence. The OECD estimates that 1%-20% of the European population is affected by ADHD annually. In the field of Child & Adneroleptic Psychiatry, CNS stimulant drugs are used to treat symptoms of ADHD. These drugs are also used to manage sleep disorders like narcolepsy and sleep apnea. The American Thoracic Society and Sleep Care Online are key players in sleep care, while pharmaceutical companies like Novartis and Independence Pharmaceuticals dominate the market. Value chain analysis, pricing analysis, and product lifecycle are essential components of the industry coverage. The competitive landscape features both cutting-edge innovators and emerging players. Inorganic growth through mergers and acquisitions is a common roadmap for market expansion. Country-level projections indicate steady growth, but challenges such as regulatory restrictions, buyers' bargaining power, suppliers' bargaining power, and the threat of substitutes pose significant restraints.

The degree of competition is high, with financial statements and product benchmarking essential for business overviews and financial details. Strengths, weaknesses, opportunities, and challenges are crucial for understanding the growth trajectory of the market. Key players include Novartis, Independence Pharmaceuticals, and other major players in the healthcare services sector. Research institutions and clinics also play a vital role in the value chain. Therefore, the increasing use of stimulants worldwide will drive the growth of the market during the forecast period.

Significant Market Trends

The increased uptake of new-generation drugs is an emerging trend in the market. For decades, first-generation anti-epileptic drugs such as phenobarbital, ethosuximide, carbamazepine, and valproic acid were in use. However, these drugs were associated with many side effects. This led to the development of second-generation anti-epileptic drugs, such as levetiracetam, topiramate, and gabapentin. Currently, new-generation of anti-epileptic drugs, which are third-generation drugs, such as rufinamide, eslicarbazepine, and lacosamide, have entered the market. Compared with the first-generation anti-epileptic drugs, the new-generation drugs have very few side effects with wide therapeutic ranges. Therefore, the uptake of new-generation anti-epileptic drugs is higher. 

The third-generation antipsychotic drugs that are used primarily for the treatment of schizophrenia and bipolar disorders are gaining popularity over first- and second-generation drugs. Antipsychotic drugs are grouped according to both the pattern of clinical action and the mechanism of action. The development of new-generation drugs with a more effective mechanism of action, coupled with fewer side actions, is expected to drive the growth of the CNS stimulant drugs market during the forecast period.

Major Market Challenge

Numerous side effects of the drugs are major challenges impeding the market growth. There are several CNS diseases that use stimulants for treatment. For instance, the medication for attention-deficit hyperactivity disorder is effective in reducing the symptoms of the disease. However, the medication is also associated with side effects. Medications such as methylphenidates, including RITALIN, Focalin, Metadate, and CONCERTA, have some potential side effects such as sleep problems, reduced appetite, increased blood pressure, headaches, stomach ache, nervousness and moodiness, and irritability.

Furthermore, amphetamines such as DEXEDRINE, Adderall, and VYVANSE have been used to improve alertness in narcolepsy. These medications are the most effective in reducing sleepiness. However, at very high doses, amphetamines can injure the brain. In addition, stimulants are widely abused globally. Abusing stimulants can have both short- and long-term effects on an individual's health, which include neurotoxicity, cardiovascular complications, seizures, and structural brain changes. Therefore, these factors will hinder the growth of the global CNS stimulant drugs market during the forecast period. 

Market Customer Landscape

The  market research report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market forecasting strategies.

Market Customer Landscape

Who are the Major Central Nervous System (CNS) Stimulant Drugs Market Companies?

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

Hisamitsu Pharmaceutical Co. Inc. - The company under this segment is engaged in the research and development, manufacturing, purchase, and sales of pharmaceuticals. The key offerings of the company include central nervous system stimulant drugs.

The central nervous system (CNS) stimulant drugs market  research report also includes detailed analyses of the competitive landscape of the market and information about 15 market Companies , including:

• Astellas Pharma Inc.
• Azurity Pharmaceuticals Inc.
• Elite Pharmaceuticals Inc.
• Ironshore
• Jazz Pharmaceuticals Plc
• KemPharm Inc.
• Merck and Co. Inc.
• Novartis AG
• Pfizer Inc.
• Purdue Pharma LP
• Sanofi SA
• Shionogi and Co. Ltd.
• Takeda Pharmaceutical Co. Ltd.
• Teva Pharmaceutical Industries Ltd.
• Tris Pharma Inc.

Qualitative and quantitative analysis of Companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize Companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize Companies as dominant, leading, strong, tentative, and weak.

Market Segment

This market report extensively covers market segmentation by distribution channel (hospitals and others), application (attention-deficit hyperactivity disorder, narcolepsy, and others), and geography (North America, Europe, Asia, and Rest of World (ROW).  Furthermore, the report includes historic market data from 2017 to 2021. The market refers to the production, sale, and use of pharmaceutical products that stimulate the central nervous system. These drugs, such as Adolescents, Psychiatry, and Sleepless Nights are known as obstructive sleep apnea (OSA), which is commonly used to treat Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy. They work by increasing the levels of certain neurotransmitters in the brain, including dopamine and norephenylenephrine. Chilblains and Sleeps, two major players in the market, offer a range of products for the treatment of ADHD and Narcolepsy. Psychiatry and senior population also utilize these drugs for various therapeutic purposes. The market for CNS Stimulant Drugs is expected to grow significantly due to the increasing prevalence of ADHD and Narcolepsy, as well as the expanding use of these drugs for off-label purposes.  

By Distribution Channel

The market share growth by the hospital segment will be significant during the forecast period. The hospital segment is an important part of the CNS stimulant drugs market, as hospitals are major consumers of these medications to treat various conditions. Within the hospital segment, CNS stimulant drugs are typically used to treat conditions such as ADHD, narcolepsy, and other sleep disorders.

Get a glance at the market contribution of various segments Request a PDF Sample

The hospitals segment was valued at USD 10.23 billion in 2017 and continued to grow until 2021. CNS stimulant drugs are used in hospitals to manage pain and help patients stay alert and focused during surgical procedures. This can help reduce the risk of complications and improve patient outcomes. Hospitals are expected to continue to be a major segment of the CNS stimulant drugs market in the coming years, as the demand for these medications is likely to remain strong. This is due to the increasing prevalence of conditions such as ADHD and the growing emphasis on pain management and the use of CNS stimulant drugs in surgical settings. Therefore, the hospital segment is expected to remain an important part of the central nervous system stimulant drugs market during the forecast period.

Regional Analysis

For more insights on the market share of various regions Request PDF Sample now!

North America is estimated to contribute 43% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

The market is experiencing significant growth, primarily driven by the rising prevalence of CNS disorders such as ADHD and autism. In 2021, 9.4% of US children and 1.52% of Canadian youth were diagnosed with these conditions. Success factors include increasing awareness and diagnosis rates, regulatory approvals, and product innovation. Current priorities include addressing competitive threats from generic drugs and expanding indications beyond ADHD. Strategies include partnerships, acquisitions, and product launches. Recent developments include FDA approvals for new indications and formulations, and collaborations between industry players and research institutions. Competitive threats include increasing competition from generics and biosimilars, as well as potential regulatory changes. Product launches, such as new formulations and indications, will continue to be a key strategy for market growth.

Additionally, the market has witnessed the approval of new stimulants to treat CNS disorders in the US. For instance, in March 2019, the US FDA approved Adhansia XR (methylphenidate) to treat children as young as six years old with attention-deficit hyperactivity disorder. Adhansia XR will be available in the form of 25-85 mg. pills. Furthermore, the US FDA approved JORNAY PM (extended-release methylphenidate), a novel formulation, which is recommended to be taken in the evening instead of in the morning to provide early morning control of symptoms of attention-deficit hyperactivity disorder in patients. Thus, such factors are expected to propel the growth of the CNS stimulant drugs market during the forecast period.

Market Analyst Overview

These drugs can lead to dependency and abuse, and their long-term use can have negative effects on the cardiovascular system. As such, it is important for healthcare professionals to carefully consider the risks and benefits of these drugs when prescribing them to patients. In conclusion, the CNS Stimulant Drugs market is a growing industry that offers significant benefits for the treatment of various neurological conditions. However, it is important to carefully consider the risks and challenges associated with these drugs to ensure their safe and effective use.

Products in this market include Adolescents and Adults amphetamines, methylphenidate, and modafinil. Producers such as Novartis, Shire, and Sun Pharma dominate the market. The market is driven by the increasing prevalence of ADHD and narcolepsy, growing awareness, and rising healthcare expenditure. However, regulatory challenges, side effects, and addiction concerns pose significant threats. The market is segmented by drug type, application, end user, and region. The methylphenidate segment holds the largest market share due to its widespread use in ADHD treatment. The psychiatry application segment is expected to grow at the highest CAGR due to increasing awareness and acceptance of stimulant drugs for treating psychiatric disorders. The Asia Pacific region is projected to be the fastest-growing market due to increasing healthcare expenditure and a large patient population.

The market refers to the production, supply, and sale of pharmaceutical products designed to stimulate the central nervous system. These drugs, including Produte, Lifecycle, Comptive, Active, Landscapes, Projections, challenges, Growth, Trajectories, Buyers, Powers, Suppliers, Sustains, Bargaining, and Threats, are primarily used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy. CNS stimulants work by increasing the levels of certain neurotransmitters in the brain, leading to improved focus, alertness, and energy. The market for these drugs is significant, with a growing number of diagnoses and prescriptions for ADHD and other conditions. Additionally, the development of new formulations and delivery methods continues to drive innovation in the CNS stimulant Drugs market.

Segment Overview

The market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027. 

• Distribution Channel Outlook
  • Hospitals
  • Others

• Application Outlook
  • Attention-deficit hyperactivity disorder
  • Narcolepsy
  • Others

• Region Outlook
  • North America
    • The U.S.
    • Canada
  • Europe
    • The U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
    • Vietnam 
    • Others
  • Rest of World
    • Saudi Arabia
    • South Africa
    • Brazil
    • Others

Market Scope
Report Coverage	Details
Page number	161
Base year	2022
Historic period	2017-2021
Forecast period	2023-2027
Growth momentum & CAGR	Accelerate at a CAGR of 5.8%
Market growth 2023-2027	USD 6.49 billion
Market structure	Fragmented
YoY growth 2022-2023(%)	5.6
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 43%
Key countries	US, Canada, UK, Germany, and China
Competitive landscape	Leading Companies , Market Positioning of Companies , Competitive Strategies, and Industry Risks
Key companies profiled	Astellas Pharma Inc., Azurity Pharmaceuticals Inc., Elite Pharmaceuticals Inc., Hisamitsu Pharmaceutical Co. Inc., Ironshore, Jazz Pharmaceuticals Plc, KemPharm Inc., Merck and Co. Inc., Novartis AG, Pfizer Inc., Purdue Pharma LP, Sanofi SA, Shionogi and Co. Ltd., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Tris Pharma Inc., Viatris Inc., and Thermo Fisher Scientific Inc.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.
Customization purview	If our market growth analysis report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Get access to Report Sample PDF !

What are the Key Data Covered in this Market Research and Growth Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the market growth and forecasting between 2023 and 2027
• Precise estimation of the size of the central nervous system (CNS) stimulant drugs market size and its contribution to the parent market
• Accurate predictions about upcoming market trends and changes in consumer behavior
• Growth of the industry across North America, Europe, Asia, and Rest of World (ROW)
• A thorough analysis of the market’s competitive landscape and detailed information about Companies
• Comprehensive analysis of factors that will challenge the growth of  market Companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch